Article (Scientific journals)
European Respiratory Society guidelines for the diagnosis of asthma in adults
Louis, Renaud; Satia, I.; Ojanguren, I. et al.
2022In European Respiratory Journal, 60 (3)
Peer Reviewed verified by ORBi
 

Files


Full Text
LOUIS 2022_European Respiratory Society guidelines for the diagnosis_ERJ_ppauteur.pdf
Author postprint (708.11 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Although asthma is very common, affecting 5-10% of the population, the diagnosis of asthma in adults remains a challenge in the real world, which results in both over- and under-diagnosis. A taskforce was set up by the European Respiratory Society to systematically review the literature on the diagnostic accuracy of tests used to diagnose asthma in adult patients and provide recommendations for clinical practice. The taskforce defined eight Population, Index, Comparator and Outcome questions that were assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach. The taskforce utilised the outcomes to develop an evidence-based diagnostic algorithm, with recommendations for a pragmatic guideline for everyday practice that was directed by real-life patient experiences. The taskforce supports the initial use of spirometry followed by bronchodilator reversibility testing (if airway obstruction is present). If initial spirometry fails to show obstruction, further tests should be performed in the following order: exhaled nitric oxide fraction, peak expiratory flow variability, or, in secondary care, bronchial challenge. We present the thresholds for each test that are compatible with a diagnosis of asthma in the presence of current symptoms. The taskforce reinforces spirometry as a priority and recognises the value of measuring blood eosinophils and serum immunoglobulin E to phenotype the patient. Measuring gas trapping by body plethysmography in patients with preserved forced expiratory volume in 1 s/forced vital capacity ratio deserves further attention. The taskforce draws attention to the difficulty of making a correct diagnosis in patients already receiving inhaled corticosteroids; the comorbidities that may obscure diagnosis; the importance of phenotyping; and the necessity of considering the patient experience in the diagnostic process. Copyright © The authors 2022.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Louis, Renaud ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Satia, I.;  Division of Respirology, McMaster University, Hamilton, ON, Canada
Ojanguren, I.;  Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Universitat Autònomona de Barcelona (UAB), Vall d'Hebron Institut de Recerca (VHIR), CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain
Schleich, FLorence ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Bonini, M.;  Sapienza University of Rome, Rome, Italy
Tonia, T.;  Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Rigau, D.;  Iberoamerican Cochrane Centre, Barcelona, Spain
Brinke, A.T.;  Pulmonology, Medical Center Leeuwarden, Leeuwarden, Netherlands
Buhl, R.;  Pulmonary Dept, Mainz University Hospital, Mainz, Germany
Loukides, S.;  University of Athens, Athens, Greece
Kocks, J.W.H.;  General Practitioners Research Institute, Groningen, Netherlands
Boulet, L.-P.;  Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC, Canada
Bourdin, A.;  University of Montpellier, Montpellier, France
Coleman, C.;  European Lung Foundation, Sheffield, United Kingdom
Needham, K.;  European Lung Foundation, Sheffield, United Kingdom
Thomas, M.;  Primary Care and Population Sciences Division, University of Southampton, Southampton, United Kingdom
Idzko, M.;  Dept of Respiratory Medicine, Medical University of Vienna, Vienna, Austria
Papi, A.;  Respiratory Medicine, University of Ferrara, Ferrara, Italy
Porsbjerg, C.;  Respiratory Medicine, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark
Schuermans, D.;  Respiratory Division, Academic Hospital UZBrussel, Brussels, Belgium
Soriano, J.B.;  Universidad Autónoma de Madrid, Hospital Universitario de la Princesa, Madrid, Spain
Usmani, O.S.;  National Heart and Lung Institute, Imperial College London, London, United Kingdom
More authors (12 more) Less
Language :
English
Title :
European Respiratory Society guidelines for the diagnosis of asthma in adults
Publication date :
2022
Journal title :
European Respiratory Journal
ISSN :
0903-1936
eISSN :
1399-3003
Publisher :
European Respiratory Society
Volume :
60
Issue :
3
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
Conflict of interest: R. Louis reports grants and personal fees from GSK, AZ, Chiesi and Novartis, personal fees from Sanofi, outside the submitted work. I. Satia reports grants and personal fees from GSK and Merck, personal fees from AstraZeneca, grants from ERS Respire 3 Marie Curie Fellowship and E.J. Moran Campbell Early Career Award, outside the submitted work. I. Ojanguren reports grants and personal fees from AstraZeneca, Sanofi and GSK, personal fees and non-financial support from Boehringer Ingelheim and Chiesi, grants, personal fees and non-financial support from Novartis, personal fees from MSD, Puretech, Bial and TEVA, outside the submitted work. F. Schleich reports grants and personal fees for national board participation and presentations from GSK and AstraZeneca, personal fees for board participation and lectures from Chiesi, outside the submitted work. M. Bonini has nothing to disclose. T. Tonia reports acting as ERS Methodologist. D. Rigau worked as ERS methodologist until February 2020. A. ten Brinke reports institutional fees for research advisory board work from GSK, Sanofi, TEVA, AstraZeneca and Boehringer Ingelheim, institutional fees for lectures from AstraZeneca, GSK, TEVA and SanofiGenzyme, grants from AstraZeneca, GSK and TEVA, outside the submitted work. R. Buhl reports personal fees from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Novartis, Sanofi, Roche and Teva, and grants to Mainz University Hospital from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Roche, all outside the submitted work. S. Loukides has nothing to disclose. J.W.H. Kocks reports grants, institutional fees and non-financial support from AstraZeneca and Boehringer Ingelheim, grants and institutional fees from Chiesi Pharmaceuticals, GSK, Novartis and TEVA, institutional fees from MSD and COVIS, outside the submitted work; and holds 72.5% of shares in the General Practitioners Research Institute. L-P. Boulet reports grants from Amgen, AstraZeneca, GlaxoSmithKline, Merck, Novartis and Sanofi-Regeneron, personal fees for consultancy and advisory board work from AstraZeneca, Novartis, GlaxoSmithKline, Merck and Sanofi-Regeneron, personal fees for lectures from AstraZeneca, Covis, GlaxoSmithKline, Novartis, Merck and Sanofi, grants and non-financial support from AstraZeneca, Covis, GlaxoSmithKline, Merck and Novartis, and is Chair of Global Initiative for Asthma (GINA) Board of Directors, President of the Global Asthma Organisation (Interasma) and Member of the Canadian Thoracic Society Respiratory Guidelines Committee. A. Bourdin reports grants, personal fees, non-financial support and other (investigator in clinical trials) from GSK, AstraZeneca, Boeringher Ingelheim and Actelion/Jansen, personal fees, non-financial support and other (investigator in clinical trials) from Novartis, Chiesi Farma, Sanofi Regeneron and Roche, non-financial support and other (investigator in clinical trials) from Teva, other (investigator in clinical trials) from United Therapeutics and Pulsar, outside the submitted work. C. Coleman is an employee of European Lung Foundation. K. Needham has nothing to disclose. M. Thomas reports personal fees from GSK, Boehringer Ingelheim and Chiesi, outside the submitted work. M. Idzko has nothing to disclose. A. Papi reports board membership, consultancy, payment for lectures, grants for research and travel expenses reimbursement from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici and TEVA, board membership, consultancy, payment for lectures and travel expenses reimbursement from Mundipharma, Zambon, Novartis and Sanofi/Regeneron, grants for research, payment for lectures and travel expenses reimbursement from Menarini, board membership, consultancy and travel expenses reimbursement from Roche, grants from Fondazione Maugeri and Fondazione Chiesi, personal fees for consultancy from Edmondpharma, outside the submitted work. C. Porsbjerg reports grants and personal fees from Astra Zeneca, GSK, Novartis, TEVA, Sanofi and Chiesi, grants from Pharmaxis, outside the submitted work. D. Schuermans reports non-financial support from Free University of Brussels, outside the submitted work. J.B. Soriano has nothing to disclose. O.S. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi and GlaxoSmithKline, grants from Edmond Pharma, personal fees from Napp, Mundipharma, Sandoz, Takeda, Cipla, Covis, Novartis, Mereo Biopharma, Orion, Menarini, Ucb, Trudell Medical, Deva and Kamada, outside the submitted work.
Available on ORBi :
since 25 November 2022

Statistics


Number of views
177 (6 by ULiège)
Number of downloads
90 (3 by ULiège)

Scopus citations®
 
85
Scopus citations®
without self-citations
71
OpenCitations
 
60

Bibliography


Similar publications



Contact ORBi